Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Nov 1;5(11):e2244350.
doi: 10.1001/jamanetworkopen.2022.44350.

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer

Affiliations
Multicenter Study

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer

Catherine Owusuaa et al. JAMA Netw Open. .

Abstract

Importance: To optimize palliative care in patients with cancer who are in their last year of life, timely and accurate prognostication is needed. However, available instruments for prognostication, such as the surprise question ("Would I be surprised if this patient died in the next year?") and various prediction models using clinical variables, are not well validated or lack discriminative ability.

Objective: To develop and validate a prediction model to calculate the 1-year risk of death among patients with advanced cancer.

Design, setting, and participants: This multicenter prospective prognostic study was performed in the general oncology inpatient and outpatient clinics of 6 hospitals in the Netherlands. A total of 867 patients were enrolled between June 2 and November 22, 2017, and followed up for 1 year. The primary analyses were performed from October 9 to 25, 2019, with the most recent analyses performed from June 19 to 22, 2022. Cox proportional hazards regression analysis was used to develop a prediction model including 3 categories of candidate predictors: clinician responses to the surprise question, patient clinical characteristics, and patient laboratory values. Data on race and ethnicity were not collected because most patients were expected to be of White race and Dutch ethnicity, and race and ethnicity were not considered as prognostic factors. The models' discriminative ability was assessed using internal-external validation by study hospital and measured using the C statistic. Patients 18 years and older with locally advanced or metastatic cancer were eligible. Patients with hematologic cancer were excluded.

Main outcomes and measures: The risk of death by 1 year.

Results: Among 867 patients, the median age was 66 years (IQR, 56-72 years), and 411 individuals (47.4%) were male. The 1-year mortality rate was 41.6% (361 patients). Three prediction models with increasing complexity were developed: (1) a simple model including the surprise question, (2) a clinical model including the surprise question and clinical characteristics (age, cancer type prognosis, visceral metastases, brain metastases, Eastern Cooperative Oncology Group performance status, weight loss, pain, and dyspnea), and (3) an extended model including the surprise question, clinical characteristics, and laboratory values (hemoglobin, C-reactive protein, and serum albumin). The pooled C statistic was 0.69 (95% CI, 0.67-0.71) for the simple model, 0.76 (95% CI, 0.73-0.78) for the clinical model, and 0.78 (95% CI, 0.76-0.80) for the extended model. A nomogram and web-based calculator were developed to support clinicians in adequately caring for patients with advanced cancer.

Conclusions and relevance: In this study, a prediction model including the surprise question, clinical characteristics, and laboratory values had better discriminative ability in predicting death among patients with advanced cancer than models including the surprise question, clinical characteristics, or laboratory values alone. The nomogram and web-based calculator developed for this study can be used by clinicians to identify patients who may benefit from palliative care and advance care planning. Further exploration of the feasibility and external validity of the model is needed.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Aerts reported receiving grants from AstraZeneca and Bristol-Myers Squibb; personal fees from Amphera, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck Sharp & Dohme, and Takeda Pharmaceutical Company; and being a shareholder of Amphera outside the submitted work. Dr van der Rijt reported receiving grants from the Netherlands Organization for Health Research and Development during the conduct of the study and personal fees from Kyowa Kirin Co (via her institution) outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Kaplan-Meier Survival Curve
Survival among 867 patients with advanced cancer.
Figure 2.
Figure 2.. Nomogram of the Extended Model
The surprise question was, “Would I be surprised if this patient died in the next year?” Instructions for use of the nomogram: (1) locate the answer to the surprise question, (2) draw a straight line upward to the point axis, (3) repeat this procedure for the other 11 predictors (age, cancer type prognosis, visceral metastases, brain metastasis, ECOG performance status, weight loss, pain, dyspnea, hemoglobin, C-reactive protein, and serum albumin), (4) sum the points for all predictors on the total points axis, and (5) draw a line straight down to the 1-year probability of dying axis to find the patient’s risk of dying within 1 year. Conventional unit conversion factors: To convert hemoglobin from millimoles per liter to grams per deciliter, multiply by 1.6113; to convert C-reactive protein from milligrams per liter to milligrams per deciliter, divide by 10; to convert serum albumin from grams per liter to grams per deciliter, divide by 10. CTCAE indicates Common Terminology Criteria for Adverse Events; ECOG, Eastern Cooperative Oncology Group; and NRS, numerical rating scale.

References

    1. Ahmedzai SH, Costa A, Blengini C, et al. ; International Working Group Convened by the European School of Oncology . A new international framework for palliative care. Eur J Cancer. 2004;40(15):2192-2200. doi:10.1016/j.ejca.2004.06.009 - DOI - PubMed
    1. Jordan K, Aapro M, Kaasa S, et al. . European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol. 2018;29(1):36-43. doi:10.1093/annonc/mdx757 - DOI - PubMed
    1. Rietjens JAC, Sudore RL, Connolly M, et al. ; European Association for Palliative Care . Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol. 2017;18(9):e543-e551. doi:10.1016/S1470-2045(17)30582-X - DOI - PubMed
    1. Rome RB, Luminais HH, Bourgeois DA, Blais CM. The role of palliative care at the end of life. Ochsner J. 2011;11(4):348-352. - PMC - PubMed
    1. Glare PA, Sinclair CT. Palliative medicine review: prognostication. J Palliat Med. 2008;11(1):84-103. doi:10.1089/jpm.2008.9992 - DOI - PubMed

Publication types